Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging

Authors:

Abstract
Significance: Primary and metastatic liver cancers that are associated with high mortality rates and poor treatment responses are only diagnosed at late stages, due to the lack of highly sensitive contrast agents and robust imaging methodologies. We have developed a protein MRI contrast agent (ProCA32) by engineering high-affinity Gd 3+ -binding pockets in rat and human α-parvalbumin. ProCA32 can function as both a T 1 - and T 2 -weighted contrast agent, which enables noninvasive detection of early-stage micrometastatic liver tumors with sizes as small as 0.24 mm using T 1 - and T 2 -weighted or T 2 /T 1 ratio MRI. Our protein-based MRI contrast agents and imaging methodology are expected to provide robust results for the early detection of liver cancer as well as other liver diseases.
Funding Information
  • HHS | National Institutes of Health (EB007268, GM62999, CA118113)
  • HHS | National Institutes of Health (CA176001, P30EY06360)
  • HHS | National Institutes of Health (S10RR023706)

This publication has 33 references indexed in Scilit: